Maruf Mahir, Brancato Sam J, Agarwal Piyush K
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cancer Biol Med. 2016 Jun;13(2):194-205. doi: 10.20892/j.issn.2095-3941.2016.0020.
Intravesical Bacillus Calmette-Guérin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, modify, or enhance the immune response. Such strategies include recombinant BCG, monoclonal antibodies, vaccines, gene therapy, and adoptive T-cell therapy. Here, we review the emerging immunotherapeutics in the treatment of nonmuscle invasive bladder cancer.
膀胱内灌注卡介苗（BCG）长期以来一直是非肌肉浸润性膀胱癌的金标准治疗方法。最近，新型免疫治疗药物不断涌现，这些药物在尿路上皮细胞癌的治疗中显示出了前景。这些药物旨在增强、调节或强化免疫反应。此类策略包括重组卡介苗、单克隆抗体、疫苗、基因治疗和过继性T细胞治疗。在此，我们综述了非肌肉浸润性膀胱癌治疗中新兴的免疫治疗方法。
Zotero 插件